Jaguar Health (JAGX) Non-Current Deffered Revenue (2015 - 2026)
Jaguar Health (JAGX) posted quarterly Non-Current Deffered Revenue of $340000.0 for Q1 2026, down 33.33% year-over-year from $510000.0 in Q1 2025, and down 10.99% quarter-over-quarter from $382000.0 in Q4 2025.
Jaguar Health (JAGX) Non-Current Deffered Revenue (2015 - 2026) Analysis & Trends
Jaguar Health (JAGX) has reported Non-Current Deffered Revenue for 6 consecutive years, with $340000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue fell 33.33% year-over-year to $340000.0; the TTM figure through Mar 2026 stood at $340000.0 (down 33.33% YoY), while the FY2025 annual figure was $382000.0, down 30.92% from the prior year.
- Non-Current Deffered Revenue declined to $340000.0 in Q1 2026 per JAGX's latest filing, from $382000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $680000.0 in Q1 2024 and bottomed at $340000.0 in Q1 2026.
- Historically, Non-Current Deffered Revenue has averaged $510111.1 across 3 years, with a median of $510000.0 in 2025.
- Annual changes were most pronounced in 2025 — Non-Current Deffered Revenue slipped 25.0% — and 2026, when it plunged 33.33%.
- Jaguar Health's Non-Current Deffered Revenue stood at $553000.0 in 2024, then tumbled by 30.92% to $382000.0 in 2025, then retreated by 10.99% to $340000.0 in 2026.
- Business Quant data shows JAGX's Non-Current Deffered Revenue at $340000.0 in Q1 2026, $382000.0 in Q4 2025, and $425000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Jaguar Health | 447,549.24 | -9.62 Mn | 19.11 Mn | 340,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 340,000.00 |
| Dec 31, 2025 | 382,000.00 |
| Sep 30, 2025 | 425,000.00 |
| Jun 30, 2025 | 468,000.00 |
| Mar 31, 2025 | 510,000.00 |
| Dec 31, 2024 | 553,000.00 |
| Sep 30, 2024 | 595,000.00 |
| Jun 30, 2024 | 638,000.00 |
| Mar 31, 2024 | 680,000.00 |
| Jun 30, 2017 | 7,271.00 |
| Mar 31, 2017 | 7,114.00 |
| Dec 31, 2016 | 6,956.00 |
| Sep 30, 2016 | 6,799.00 |
| Jun 30, 2016 | 6,642.00 |
| Mar 31, 2016 | 4,981.00 |
| Dec 31, 2015 | 3,321.00 |
| Sep 30, 2015 | 1,660.00 |